Agnico Eagle Mines Ltd vs Bristol-Myers Squibb Co — how do they compare? Agnico Eagle Mines Ltd trades at $186.95 (market cap $92.01B), while Bristol-Myers Squibb Co trades at $63.25 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| AEM | BMY | |
|---|---|---|
Market Cap | $92.01B | $129.94B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $65.89 |
52-Week Low | $130.23 | $42.60 |
Enterprise Value | $88.85B | $163.92B |
Dividend Yield | 0.99% | 3.96% |
Signals from Pluang's Aura AI — not financial advice
Agnico Eagle Mines (AEM) trades at $180.48, up 0.93% today, with strong quarterly earnings beats and bullish analyst consensus. The stock shows robust fundamentals with a P/E of 15.56, net income margin of 40.44%, and record free cash flow of $6.82B in 2025. Recent news highlights operational strength amid gold price gains, though cost pressures are noted.
Outlook remains positive with a $219.63 price target and 67.7% buy ratings, supported by organic growth plans. Risks include rising production costs and gold price volatility. The stock offers upside potential but faces margin compression headwinds in 2026.
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →